Barbara K. Burton, MD, is a Professor of Pediatrics at the Northwestern University Feinberg School of Medicine and Clinical Practice Director and Director of the Phenylketonuria (PKU) Treatment Program in the Division of Genetics, Birth Defects and Metabolism at the Ann & Robert H. Lurie Children’s Hospital of Chicago. Her major clinical and research interests are in the area of inborn errors of metabolism. She is Board Certified in Pediatrics, Clinical Genetics and Clinical Biochemical Genetics. She is the past President of the Chicago Pediatric Society, and past President of the Society for Inherited Metabolic Disorders. She is a member of the Genetic and Metabolic Advisory Committee to the Illinois Department of Public Health and is Chairman of the Lysosomal Storage Disorders Subcommittee. She has contributed over 200 articles and chapters to medical literature, many of them focusing on the diagnosis and treatment of inborn errors of metabolism and on the prenatal diagnosis of genetic disorders.
Dan Oppenheimer, Ph.D.
Dan Oppenheimer, Ph.D. is Chief Operating Officer at Reset Therapeutics, a biotechnology company developing therapeutics for diseases linked to dysfunctional circadian rhythms. Previously, Dan was Group Vice President, Development and Portfolio Strategy at BioMarin Pharmaceutical, with responsibility for pipeline product development, product strategy, and portfolio planning. He previously served in several roles in Business Development and Product Development at BioMarin. During his fourteen years at BioMarin, Dan was involved in the development and approval of four therapeutics, as well as several other preclinical and clinical stage programs currently in development. Prior to joining BioMarin, Dan was a consultant at McKinsey and Company in San Francisco, advising biotechnology companies. He earned a Ph.D. in Entomology from the University of California, Berkeley, an M.B.A. at the University of Chicago Graduate School of Business and a B.A. in Molecular Biology and Biochemistry from Wesleyan University.
Luke Gelinas, Ph.D.
Luke Gelinas is a Fellow in Research Ethics at the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard Law School. Luke earned his PhD in 2014 from the University of Toronto, where he was a graduate fellow at the University of Toronto’s Centre for Ethics; he also has an MA in Religion summa cum laude from Yale Divinity School. Most recently, Luke completed a Postdoctoral Fellowship in Bioethics at the National Institutes of Health and training in Clinical Ethics at Albany Medical College. Luke’s research interests focus primarily on the concept of informed consent. Currently, his work advances several projects as part of the Harvard Catalyst Regulatory Foundations, Ethics, and Law Program, with a particular emphasis on the regulatory, ethical, and practical aspects associated with recruitment and retention of research participants.
Kendra Gottsleben, B.A.
Kendra Gottsleben is a Marketing Communication Specialist, author, and spokesperson on living a life with a rare disease and disability. Her career blends the two worlds in which she grew up: medicine and education. Kendra provides support to families and children who have severe or life-threatening illnesses or disabilities. She has defined her life by a positive outlook and success in overcoming obstacles, and refuses to be defined by MPS — the rare genetic condition she has had since birth. Watch her inspirational TED talk, "When Life Gives You Lemons."